# Efficacy and Safety Study of the Combined Oral Contraceptive NOMAC-E2 Compared to a COC Containing DRSP/EE (292002)(P05722)

- Full Text View
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record

Study Type: | Interventional |
---|---|

Study Design: | Allocation: Randomized; Endpoint Classification: Safety/Efficacy Study; Intervention Model: Parallel Assignment; Masking: Open Label; Primary Purpose: Prevention |

Condition: |
Contraception |

Interventions: |
Drug: NOMAC-E2 Drug: DRSP-EE |

Participant Flow

Recruitment Details

Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations |
---|

This study recruited participants from North America and South America |

Pre-Assignment Details

Significant events and approaches for the overall study following participant enrollment, but prior to group assignment |
---|

In total, 2281 participants were randomized (NOMAC-E2 n=1710; DRSP-EE n=571) but 2220 participants were treated (NOMAC-E2 n=1666; DRSP-EE n=554). |

Reporting Groups

Description | |
---|---|

NOMAC-E2 | Monophasic combined oral contraceptive (COC) tablets containing 2.5 mg Nomegestrol Acetate (NOMAC) and 1.5 mg Estradiol (E2) taken once daily from Day 1 of menstrual period up to and including Day 28 (Days 1-24, active tablets; Days 25-28, placebo tablets) for 13 consecutive 28-day menstrual cycles (1 year). |

DRSP-EE | Monophasic COC tablets containing 3 mg Drospirenone (DRSP) and 30 mcg Ethinyl Estradiol (EE) taken once daily from Day 1 of menstrual period up to and including Day 28 (Days 1-21, active tablets; Days 22-28, placebo tablets) for 13 consecutive 28-day menstrual cycles (1 year). |

Participant Flow: Overall Study

NOMAC-E2 | DRSP-EE | |
---|---|---|

STARTED | 1666 | 554 |

COMPLETED | 988 | 344 |

NOT COMPLETED | 678 | 210 |

Adverse event/serious adverse event | 289 | 56 |

Pre-treatment (serious) adverse event | 1 | 0 |

Withdrawal of informed consent | 111 | 36 |

Pregnancy | 15 | 5 |

Pregnancy wish | 17 | 6 |

Lost to Follow-up | 175 | 73 |

Other reason | 70 | 34 |

Baseline Characteristics

Population Description

Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate. |
---|

No text entered. |

Reporting Groups

Description | |
---|---|

NOMAC-E2 | Monophasic combined oral contraceptive (COC) tablets containing 2.5 mg Nomegestrol Acetate (NOMAC) and 1.5 mg Estradiol (E2) taken once daily from Day 1 of menstrual period up to and including Day 28 (Days 1-24, active tablets; Days 25-28, placebo tablets) for 13 consecutive 28-day menstrual cycles (1 year). |

DRSP-EE | Monophasic COC tablets containing 3 mg Drospirenone (DRSP) and 30 mcg Ethinyl Estradiol (EE) taken once daily from Day 1 of menstrual period up to and including Day 28 (Days 1-21, active tablets; Days 22-28, placebo tablets) for 13 consecutive 28-day menstrual cycles (1 year). |

Total | Total of all reporting groups |

Baseline Measures

NOMAC-E2 | DRSP-EE | Total | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|

Overall Participants Analyzed [Units: Participants] |
1666 | 554 | 2220 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||

Age [Units: Years] Mean (Standard Deviation) |
27.6 (7.2) | 27.8 (7.0) | 27.7 (7.1) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||

Gender [Units: Participants] |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||

Female | 1666 | 554 | 2220 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||

Male | 0 | 0 | 0 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||

Outcome Measures

1. Primary: | Number of In-treatment Pregnancies (With +2 Day Window) Per 100 Woman Years of Exposure (Pearl Index) [ Time Frame: 1 year (13 cycles) ] |

Measure Type | Primary |
---|---|

Measure Title | Number of In-treatment Pregnancies (With +2 Day Window) Per 100 Woman Years of Exposure (Pearl Index) |

Measure Description | In-treatment pregnancies were pregnancies with an estimated date of conception from the day of first intake of trial medication up to and including the day of last (active or placebo) intake of trial medication extended with a maximum of two days. Each 13 cycles (28 days per cycle) of exposure constitutes a woman year. The Pearl Index was obtained by dividing the number of in-treatment pregnancies that occurred by the time (in 100 women years) that the women were under risk of becoming pregnant. |

Time Frame | 1 year (13 cycles) |

Safety Issue | No |

Population Description

Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate. |
---|

The "restricted ITT" set included all participants treated except for 27 nonpregnant participants whose exposure was excluded due to limited credibility of diary data, & also excluded nonpregnant participants without >= 1 cycle expected to be at risk for pregnancy (with recorded use of condoms or w/o sexual intercourse, based on e-diary data). |

Reporting Groups

Description | |
---|---|

NOMAC-E2 | Monophasic combined oral contraceptive (COC) tablets containing 2.5 mg Nomegestrol Acetate (NOMAC) and 1.5 mg Estradiol (E2) taken once daily from Day 1 of menstrual period up to and including Day 28 (Days 1-24, active tablets; Days 25-28, placebo tablets) for 13 consecutive 28-day menstrual cycles (1 year). |

DRSP-EE | Monophasic COC tablets containing 3 mg Drospirenone (DRSP) and 30 mcg Ethinyl Estradiol (EE) taken once daily from Day 1 of menstrual period up to and including Day 28 (Days 1-21, active tablets; Days 22-28, placebo tablets) for 13 consecutive 28-day menstrual cycles (1 year). |

Measured Values

NOMAC-E2 | DRSP-EE | |
---|---|---|

Participants Analyzed [Units: Participants] |
1370 | 444 |

Units Analyzed (Woman years (rounded to nearest integer)) [Units: Woman years (rounded to nearest integer)] |
684 | 233 |

Number of In-treatment Pregnancies (With +2 Day Window) Per 100 Woman Years of Exposure (Pearl Index) [Units: Pregnancies per 100 woman years] Number (95% Confidence Interval) |
||

Overall group |
1.754 (0.9061 to 3.0632) |
3.005 (1.2082 to 6.1917) |

=<35 years old (n=1158; n=378) |
1.963 (0.9798 to 3.5119) |
3.092 (1.1347 to 6.7299) |

>35 years old (n=212; n=66) |
0.807 (0.0204 to 4.4977) |
2.572 (0.0651 to 14.33) |

No statistical analysis provided for Number of In-treatment Pregnancies (With +2 Day Window) Per 100 Woman Years of Exposure (Pearl Index)

2. Primary: | Number of In-treatment Pregnancies (With +14 Day Window) Per 100 Woman Years of Exposure (Pearl Index) [ Time Frame: 1 year (13 cycles) ] |

Measure Type | Primary |
---|---|

Measure Title | Number of In-treatment Pregnancies (With +14 Day Window) Per 100 Woman Years of Exposure (Pearl Index) |

Measure Description | In-treatment pregnancies were pregnancies with an estimated date of conception from the day of first intake of trial medication up to and including the day of last (active or placebo) intake of trial medication extended with a period of 14 days. Each 13 cycles (28 days per cycle) of exposure constitutes a woman year. The Pearl Index was obtained by dividing the number of in-treatment pregnancies that occurred by the time (in 100 women years) that the women were under risk of becoming pregnant. |

Time Frame | 1 year (13 cycles) |

Safety Issue | No |

Population Description

Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate. |
---|

The "restricted ITT" set included all participants treated except for 27 nonpregnant participants whose exposure was excluded due to limited credibility of diary data, & also excluded nonpregnant participants without >= 1 cycle expected to be at risk for pregnancy (with recorded use of condoms or w/o sexual intercourse, based on e-diary data). |

Reporting Groups

Description | |
---|---|

NOMAC-E2 | |

DRSP-EE |

Measured Values

NOMAC-E2 | DRSP-EE | |
---|---|---|

Participants Analyzed [Units: Participants] |
1370 | 444 |

Units Analyzed (Woman years (rounded to nearest integer)) [Units: Woman years (rounded to nearest integer)] |
684 | 233 |

Number of In-treatment Pregnancies (With +14 Day Window) Per 100 Woman Years of Exposure (Pearl Index) [Units: Pregnancies per 100 woman years] Number (95% Confidence Interval) |
||

Overall group |
2.192 (1.2268 to 3.6154) |
4.293 (2.0587 to 7.8951) |

=<35 years old (n=1158; n=378) |
2.498 (1.3657 to 4.1913) |
4.638 (2.1208 to 8.8042) |

>35 years old (n=212; n=66) |
0.807 (0.0204 to 4.4977) |
2.572 (0.0651 to 14.33) |

No statistical analysis provided for Number of In-treatment Pregnancies (With +14 Day Window) Per 100 Woman Years of Exposure (Pearl Index)

3. Secondary: | Number of Participants With an Occurrence of Breakthrough Bleeding/Spotting [ Time Frame: Every 28-day cycle for 13 cycles (one year total) ] |

Measure Type | Secondary |
---|---|

Measure Title | Number of Participants With an Occurrence of Breakthrough Bleeding/Spotting |

Measure Description | Cycle control was evaluated on the basis of vaginal bleeding pattern as recorded daily by participants using e-diaries. Participants documented whether vaginal bleeding was present, and if present, indicated whether it was considered to be spotting or bleeding. Breakthrough bleeding/spotting was defined as any episode that occurred during the "expected non-bleeding period" that was neither an early nor a continued withdrawal bleeding. Expected non-bleeding period: DRSP-EE group: 21-day period starting on Day 1 of the cycle; NOMAC-E2: 21-day period starting on Day 4 of the cycle. |

Time Frame | Every 28-day cycle for 13 cycles (one year total) |

Safety Issue | No |

Population Description

The ITT group consisted of all participants who were treated; ITT analyses of vaginal bleeding patterns were based on all participants in the ITT group who had at least one evaluable cycle. Cycles were considered to be non-evaluable in case of insufficient bleeding data or improper cycle length. n= number of participants with evaluable cycles. |

Reporting Groups

Description | |
---|---|

NOMAC-E2 | |

DRSP-EE |

Measured Values

NOMAC-E2 | DRSP-EE | |
---|---|---|

Participants Analyzed [Units: Participants] |
1312 | 436 |

Number of Participants With an Occurrence of Breakthrough Bleeding/Spotting [Units: Participants] |
||

Cycle 1 (n=1202 NOMAC-E2; n=398 DRSP-EE) | 370 | 84 |

Cycle 2 (n=950 NOMAC-E2; n=308 DRSP-EE) | 243 | 55 |

Cycle 3 (n=812 NOMAC-E2; n=256 DRSP-EE) | 196 | 40 |

Cycle 4 (n=739 NOMAC-E2; n=236 DRSP-EE) | 152 | 34 |

Cycle 5 (n=671 NOMAC-E2; n=229 DRSP-EE) | 139 | 29 |

Cycle 6 (n=628 NOMAC-E2; n=207 DRSP-EE) | 125 | 18 |

Cycle 7 (n=565 NOMAC-E2; n=196 DRSP-EE) | 104 | 25 |

Cycle 8 (n=543 NOMAC-E2; n=189 DRSP-EE) | 97 | 23 |

Cycle 9 (n=507 NOMAC-E2; n=173 DRSP-EE) | 85 | 30 |

Cycle 10 (n=491 NOMAC-E2; n=170 DRSP-EE) | 93 | 29 |

Cycle 11 (n=456 NOMAC-E2; n=160 DRSP-EE) | 83 | 27 |

Cycle 12 (n=428 NOMAC-E2; n=152 DRSP-EE) | 70 | 15 |

Cycle 13 (n=383 NOMAC-E2; n=133 DRSP-EE) | 62 | 20 |

No statistical analysis provided for Number of Participants With an Occurrence of Breakthrough Bleeding/Spotting

4. Secondary: | Number of Participants With an Occurrence of Absence of Withdrawal Bleeding [ Time Frame: Every 28-day cycle for 13 cycles (one year total) ] |

Measure Type | Secondary |
---|---|

Measure Title | Number of Participants With an Occurrence of Absence of Withdrawal Bleeding |

Measure Description | Cycle control was evaluated on the basis of vaginal bleeding pattern as recorded daily by participants using e-diaries. Participants documented whether vaginal bleeding was present, and if present, indicated whether it was considered to be spotting or bleeding. Absence of withdrawal bleeding was defined as no bleeding/spotting episode that began during or continued into the "expected bleeding period". Expected bleeding period: DRSP-EE group: 7-day period starting on Day 22 of the cycle; NOMAC-E2: 7-day period starting on Day 25 of the cycle and ending on Day 3 of the next cycle. |

Time Frame | Every 28-day cycle for 13 cycles (one year total) |

Safety Issue | No |

Population Description

The ITT group consisted of all participants who were treated; ITT analyses of vaginal bleeding patterns were based on all participants in the ITT group who had at least one evaluable cycle. Cycles were considered to be non-evaluable in case of insufficient bleeding data or improper cycle length. n= number of participants with evaluable cycles. |

Reporting Groups

Description | |
---|---|

NOMAC-E2 | |

DRSP-EE |

Measured Values

NOMAC-E2 | DRSP-EE | |
---|---|---|

Participants Analyzed [Units: Participants] |
1312 | 436 |

Number of Participants With an Occurrence of Absence of Withdrawal Bleeding [Units: Participants] |
||

Cycle 1 (n=1202 NOMAC-E2; n=398 DRSP-EE) | 216 | 23 |

Cycle 2 (n=950 NOMAC-E2; n=308 DRSP-EE) | 167 | 15 |

Cycle 3 (n=812 NOMAC-E2; n=256 DRSP-EE) | 178 | 15 |

Cycle 4 (n=739 NOMAC-E2; n=236 DRSP-EE) | 184 | 16 |

Cycle 5 (n=671 NOMAC-E2; n=229 DRSP-EE) | 169 | 13 |

Cycle 6 (n=628 NOMAC-E2; n=207 DRSP-EE) | 166 | 9 |

Cycle 7 (n=565 NOMAC-E2; n=196 DRSP-EE) | 139 | 13 |

Cycle 8 (n=543 NOMAC-E2; n=189 DRSP-EE) | 152 | 16 |

Cycle 9 (n=507 NOMAC-E2; n=173 DRSP-EE) | 151 | 8 |

Cycle 10 (n=491 NOMAC-E2; n=170 DRSP-EE) | 147 | 8 |

Cycle 11 (n=456 NOMAC-E2; n=160 DRSP-EE) | 156 | 6 |

Cycle 12 (n=428 NOMAC-E2; n=152 DRSP-EE) | 141 | 10 |

Cycle 13 (n=383 NOMAC-E2; n=133 DRSP-EE) | 187 | 7 |

No statistical analysis provided for Number of Participants With an Occurrence of Absence of Withdrawal Bleeding

5. Secondary: | Number of Participants With an Occurrence of Breakthrough Bleeding [ Time Frame: Every 28-day cycle for 13 cycles (one year total) ] |

Measure Type | Secondary |
---|---|

Measure Title | Number of Participants With an Occurrence of Breakthrough Bleeding |

Measure Description |
Cycle control was evaluated on the basis of vaginal bleeding pattern as recorded daily by participants using e-diaries. Participants documented whether vaginal bleeding was present, and if present, indicated whether it was considered to be spotting or bleeding. Breakthrough bleeding was defined as any bleeding episode that occurred during the "expected non-bleeding period" that was neither part of an early nor continued withdrawal bleeding. Expected non-bleeding period: DRSP-EE group: 21-day period starting on Day 1 of the cycle; NOMAC-E2: 21-day period starting on Day 4 of the cycle. |

Time Frame | Every 28-day cycle for 13 cycles (one year total) |

Safety Issue | No |

Population Description

The ITT group consisted of all participants who were treated; ITT analyses of vaginal bleeding patterns were based on all participants in the ITT group who had at least one evaluable cycle. Cycles were considered to be non-evaluable in case of insufficient bleeding data or improper cycle length. n= number of participants with evaluable cycles. |

Reporting Groups

Description | |
---|---|

NOMAC-E2 | |

DRSP-EE |

Measured Values

NOMAC-E2 | DRSP-EE | |
---|---|---|

Participants Analyzed [Units: Participants] |
1312 | 436 |

Number of Participants With an Occurrence of Breakthrough Bleeding [Units: Participants] |
||

Cycle 1 (n=1202 NOMAC-E2; n=398 DRSP-EE) | 100 | 19 |

Cycle 2 (n=950 NOMAC-E2; n=308 DRSP-EE) | 47 | 5 |

Cycle 3 (n=812 NOMAC-E2; n=256 DRSP-EE) | 43 | 5 |

Cycle 4 (n=739 NOMAC-E2; n=236 DRSP-EE) | 39 | 7 |

Cycle 5 (n=671 NOMAC-E2; n=229 DRSP-EE) | 30 | 4 |

Cycle 6 (n=628 NOMAC-E2; n=207 DRSP-EE) | 29 | 4 |

Cycle 7 (n=565 NOMAC-E2; n=196 DRSP-EE) | 31 | 5 |

Cycle 8 (n=543 NOMAC-E2; n=189 DRSP-EE) | 25 | 5 |

Cycle 9 (n=507 NOMAC-E2; n=173 DRSP-EE) | 24 | 7 |

Cycle 10 (n=491 NOMAC-E2; n=170 DRSP-EE) | 27 | 9 |

Cycle 11 (n=456 NOMAC-E2; n=160 DRSP-EE) | 19 | 5 |

Cycle 12 (n=428 NOMAC-E2; n=152 DRSP-EE) | 16 | 3 |

Cycle 13 (n=383 NOMAC-E2; n=133 DRSP-EE) | 16 | 2 |

No statistical analysis provided for Number of Participants With an Occurrence of Breakthrough Bleeding

6. Secondary: | Number of Participants With an Occurrence of Breakthrough Spotting (Spotting Only) [ Time Frame: Every 28-day cycle for 13 cycles (one year total) ] |

Measure Type | Secondary |
---|---|

Measure Title | Number of Participants With an Occurrence of Breakthrough Spotting (Spotting Only) |

Measure Description |
Cycle control was evaluated on the basis of vaginal bleeding pattern as recorded daily by participants using e-diaries. Participants documented whether vaginal bleeding was present, and if present, indicated whether it was considered to be spotting or bleeding. Breakthrough spotting was defined as any spotting episode that occurred during the "expected non-bleeding period" that was neither part of an early nor continued withdrawal bleeding. Expected non-bleeding period: DRSP-EE group: 21-day period starting on Day 1 of the cycle; NOMAC-E2: 21-day period starting on Day 4 of the cycle. |

Time Frame | Every 28-day cycle for 13 cycles (one year total) |

Safety Issue | No |

Population Description

n= number of participants with evaluable cycles. |

Reporting Groups

Description | |
---|---|

NOMAC-E2 | |

DRSP-EE |

Measured Values

NOMAC-E2 | DRSP-EE | |
---|---|---|

Participants Analyzed [Units: Participants] |
1312 | 436 |

Number of Participants With an Occurrence of Breakthrough Spotting (Spotting Only) [Units: Participants] |
||

Cycle 1 (n=1202 NOMAC-E2; n=398 DRSP-EE) | 306 | 72 |

Cycle 2 (n=950 NOMAC-E2; n=308 DRSP-EE) | 211 | 50 |

Cycle 3 (n=812 NOMAC-E2; n=256 DRSP-EE) | 168 | 36 |

Cycle 4 (n=739 NOMAC-E2; n=236 DRSP-EE) | 126 | 30 |

Cycle 5 (n=671 NOMAC-E2; n=229 DRSP-EE) | 114 | 25 |

Cycle 6 (n=628 NOMAC-E2; n=207 DRSP-EE) | 102 | 16 |

Cycle 7 (n=565 NOMAC-E2; n=196 DRSP-EE) | 85 | 20 |

Cycle 8 (n=543 NOMAC-E2; n=189 DRSP-EE) | 78 | 18 |

Cycle 9 (n=507 NOMAC-E2; n=173 DRSP-EE) | 64 | 23 |

Cycle 10 (n=491 NOMAC-E2; n=170 DRSP-EE) | 71 | 21 |

Cycle 11 (n=456 NOMAC-E2; n=160 DRSP-EE) | 67 | 22 |

Cycle 12 (n=428 NOMAC-E2; n=152 DRSP-EE) | 59 | 12 |

Cycle 13 (n=383 NOMAC-E2; n=133 DRSP-EE) | 46 | 18 |

No statistical analysis provided for Number of Participants With an Occurrence of Breakthrough Spotting (Spotting Only)

7. Secondary: | Number of Participants With an Occurrence of Early Withdrawal Bleeding [ Time Frame: Every 28-day cycle for 13 cycles (one year total) ] |

Measure Type | Secondary |
---|---|

Measure Title | Number of Participants With an Occurrence of Early Withdrawal Bleeding |

Measure Description |
Cycle control was evaluated on the basis of vaginal bleeding pattern as recorded daily by participants using e-diaries. Participants documented whether vaginal bleeding was present, and if present, indicated whether it was considered to be spotting or bleeding. Early withdrawal bleeding was defined as any withdrawal bleeding that started before the current "expected bleeding period". Expected bleeding period: DRSP-EE group: 7-day period starting on Day 22 of the cycle; NOMAC-E2: 7-day period starting on Day 25 of the cycle and ending on Day 3 of the next cycle. |

Time Frame | Every 28-day cycle for 13 cycles (one year total) |

Safety Issue | No |

Population Description

n= number of participants with evaluable cycles. |

Reporting Groups

Description | |
---|---|

NOMAC-E2 | |

DRSP-EE |

Measured Values

NOMAC-E2 | DRSP-EE | |
---|---|---|

Participants Analyzed [Units: Participants] |
1312 | 436 |

Number of Participants With an Occurrence of Early Withdrawal Bleeding [Units: Participants] |
||

Cycle 1 (n=1202 NOMAC-E2; n=398 DRSP-EE) | 175 | 46 |

Cycle 2 (n=950 NOMAC-E2; n=308 DRSP-EE) | 68 | 14 |

Cycle 3 (n=812 NOMAC-E2; n=256 DRSP-EE) | 66 | 24 |

Cycle 4 (n=739 NOMAC-E2; n=236 DRSP-EE) | 48 | 9 |

Cycle 5 (n=671 NOMAC-E2; n=229 DRSP-EE) | 36 | 11 |

Cycle 6 (n=628 NOMAC-E2; n=207 DRSP-EE) | 28 | 11 |

Cycle 7 (n=565 NOMAC-E2; n=196 DRSP-EE) | 22 | 11 |

Cycle 8 (n=543 NOMAC-E2; n=189 DRSP-EE) | 29 | 13 |

Cycle 9 (n=507 NOMAC-E2; n=173 DRSP-EE) | 17 | 9 |

Cycle 10 (n=491 NOMAC-E2; n=170 DRSP-EE) | 27 | 13 |

Cycle 11 (n=456 NOMAC-E2; n=160 DRSP-EE) | 17 | 7 |

Cycle 12 (n=428 NOMAC-E2; n=152 DRSP-EE) | 10 | 6 |

Cycle 13 (n=383 NOMAC-E2; n=133 DRSP-EE) | 9 | 6 |

No statistical analysis provided for Number of Participants With an Occurrence of Early Withdrawal Bleeding

8. Secondary: | Number of Participants With an Occurrence of Continued Withdrawal Bleeding [ Time Frame: Every 28-day cycle for 12 cycles ] |

Measure Type | Secondary |
---|---|

Measure Title | Number of Participants With an Occurrence of Continued Withdrawal Bleeding |

Measure Description |
Cycle control was evaluated on the basis of vaginal bleeding pattern as recorded daily by participants using e-diaries. Participants documented whether vaginal bleeding was present, and if present, indicated whether it was considered to be spotting or bleeding. Continued withdrawal bleeding was defined as any withdrawal bleeding that continued into the "expected non-bleeding period" of the next cycle. Expected non-bleeding period: DRSP-EE group: 21-day period starting on Day 1 of the cycle; NOMAC-E2: 21-day period starting on Day 4 of the cycle. |

Time Frame | Every 28-day cycle for 12 cycles |

Safety Issue | No |

Population Description

Reporting Groups

Description | |
---|---|

NOMAC-E2 |
n= number of participants with evaluable cycles (except for the very last cycle of a participant for which this parameter was not defined). |

DRSP-EE |
n= number of participants with evaluable cycles (except for the very last cycle of a participant for which this parameter was not defined). |

Measured Values

NOMAC-E2 | DRSP-EE | |
---|---|---|

Participants Analyzed [Units: Participants] |
1312 | 436 |

Number of Participants With an Occurrence of Continued Withdrawal Bleeding [Units: Participants] |
||

Cycle 1 (n=1179 NOMAC-E2; n=393 DRSP-EE) | 367 | 216 |

Cycle 2 (n=939 NOMAC-E2; n=304 DRSP-EE) | 309 | 174 |

Cycle 3 (n=794 NOMAC-E2; n=254 DRSP-EE) | 225 | 149 |

Cycle 4 (n=730 NOMAC-E2; n=235 DRSP-EE) | 192 | 145 |

Cycle 5 (n=659 NOMAC-E2; n=227 DRSP-EE) | 171 | 135 |

Cycle 6 (n=617 NOMAC-E2; n=207 DRSP-EE) | 149 | 122 |

Cycle 7 (n=555 NOMAC-E2; n=194 DRSP-EE) | 142 | 111 |

Cycle 8 (n=540 NOMAC-E2; n=188 DRSP-EE) | 128 | 107 |

Cycle 9 (n=503 NOMAC-E2; n=171 DRSP-EE) | 116 | 106 |

Cycle 10 (n=486 NOMAC-E2; n=169 DRSP-EE) | 121 | 95 |

Cycle 11 (n=455 NOMAC-E2; n=159 DRSP-EE) | 90 | 94 |

Cycle 12 (n=421 NOMAC-E2; n=149 DRSP-EE) | 95 | 78 |

No statistical analysis provided for Number of Participants With an Occurrence of Continued Withdrawal Bleeding

9. Secondary: | Average Number of Breakthrough Bleeding/Spotting Days [ Time Frame: Every 28-day cycle for 13 cycles (one year total) ] |

Measure Type | Secondary |
---|---|

Measure Title | Average Number of Breakthrough Bleeding/Spotting Days |

Measure Description | Cycle control was evaluated on the basis of vaginal bleeding pattern as recorded daily by participants using e-diaries. Participants documented whether vaginal bleeding was present, and if present, indicated whether it was considered to be spotting or bleeding. Breakthrough bleeding/spotting was defined as any episode that occurred during the "expected non-bleeding period" that was neither an early nor a continued withdrawal bleeding. Expected non-bleeding period: DRSP-EE group: 21-day period starting on Day 1 of the cycle; NOMAC-E2: 21-day period starting on Day 4 of the cycle. |

Time Frame | Every 28-day cycle for 13 cycles (one year total) |

Safety Issue | No |

Population Description

ITT analyses of vaginal bleeding patterns were based on all participants in the ITT group who had at least one evaluable cycle. Cycles were considered to be non-evaluable in case of insufficient bleeding data or improper cycle length. n= number of participants who had breakthrough bleeding/spotting for the respective cycle. |

Reporting Groups

Description | |
---|---|

NOMAC-E2 | |

DRSP-EE |

Measured Values

NOMAC-E2 | DRSP-EE | |
---|---|---|

Participants Analyzed [Units: Participants] |
1312 | 436 |

Average Number of Breakthrough Bleeding/Spotting Days [Units: Days] Mean (Standard Deviation) |
||

Cycle 1 (n=370 NOMAC-E2; n=84 DRSP-EE) | 4.5 (3.6) | 4.0 (2.9) |

Cycle 2 (n=243 NOMAC-E2; n=55 DRSP-EE) | 3.5 (2.7) | 2.7 (2.3) |

Cycle 3 (n=196 NOMAC-E2; n=40 DRSP-EE) | 3.2 (2.5) | 2.6 (2.0) |

Cycle 4 (n=152 NOMAC-E2; n=34 DRSP-EE) | 3.5 (2.7) | 3.2 (2.5) |

Cycle 5 (n=139 NOMAC-E2; n=29 DRSP-EE) | 3.6 (3.0) | 2.6 (2.1) |

Cycle 6 (n=125 NOMAC-E2; n=18 DRSP-EE) | 3.2 (2.7) | 3.0 (1.7) |

Cycle 7 (n=104 NOMAC-E2; n=25 DRSP-EE) | 3.9 (2.9) | 2.9 (2.0) |

Cycle 8 (n=97 NOMAC-E2; n=23 DRSP-EE) | 3.4 (2.4) | 2.6 (2.4) |

Cycle 9 (n=85 NOMAC-E2; n=30 DRSP-EE) | 3.5 (3.2) | 3.2 (2.2) |

Cycle 10 (n=93 NOMAC-E2; n=29 DRSP-EE) | 2.6 (2.1) | 3.2 (2.1) |

Cycle 11 (n=83 NOMAC-E2; n=27 DRSP-EE) | 3.6 (2.5) | 2.9 (2.0) |

Cycle 12 (n=70 NOMAC-E2; n=15 DRSP-EE) | 2.9 (2.4) | 3.1 (2.9) |

Cycle 13 (n=62 NOMAC-E2; n=20 DRSP-EE) | 2.8 (2.2) | 3.0 (1.9) |

No statistical analysis provided for Average Number of Breakthrough Bleeding/Spotting Days

10. Secondary: | Average Number of Withdrawal Bleeding/Spotting Days [ Time Frame: Every 28-day cycle for 13 cycles (one year total) ] |

Measure Type | Secondary |
---|---|

Measure Title | Average Number of Withdrawal Bleeding/Spotting Days |

Measure Description | Cycle control was evaluated on the basis of vaginal bleeding pattern as recorded daily by participants using e-diaries. Participants documented whether vaginal bleeding was present, and if present, indicated whether it was considered to be spotting or bleeding. Withdrawal bleeding was defined as bleeding/spotting episode that started during or continued into the "expected bleeding period". Expected bleeding period: DRSP-EE group: 7-day period starting on Day 22 of the cycle; NOMAC-E2: 7-day period starting on Day 25 of the cycle and ending on Day 3 of the next cycle. |

Time Frame | Every 28-day cycle for 13 cycles (one year total) |

Safety Issue | No |

Population Description

ITT analyses of vaginal bleeding patterns were based on all participants in the ITT group who had at least one evaluable cycle. Cycles were considered to be non-evaluable in case of insufficient bleeding data or improper cycle length. n= number of participants who had withdrawal bleeding/spotting for the respective cycle. |

Reporting Groups

Description | |
---|---|

NOMAC-E2 | |

DRSP-EE |

Measured Values

NOMAC-E2 | DRSP-EE | |
---|---|---|

Participants Analyzed [Units: Participants] |
1312 | 436 |

Average Number of Withdrawal Bleeding/Spotting Days [Units: Days] Mean (Standard Deviation) |
||

Cycle 1 (n=986 NOMAC-E2; n=375 DRSP-EE) | 5.7 (5.0) | 6.0 (3.5) |

Cycle 2 (n=783 NOMAC-E2; n=293 DRSP-EE) | 5.0 (4.6) | 6.2 (17.1) |

Cycle 3 (n=634 NOMAC-E2; n=241 DRSP-EE) | 4.8 (4.4) | 6.6 (18.9) |

Cycle 4 (n=555 NOMAC-E2; n=220 DRSP-EE) | 4.5 (2.9) | 6.5 (19.8) |

Cycle 5 (n=502 NOMAC-E2; n=216 DRSP-EE) | 4.5 (3.5) | 6.6 (19.9) |

Cycle 6 (n=462 NOMAC-E2; n=198 DRSP-EE) | 4.1 (2.5) | 6.6 (20.8) |

Cycle 7 (n=426 NOMAC-E2; n=183 DRSP-EE) | 4.2 (3.4) | 6.5 (21.6) |

Cycle 8 (n=391 NOMAC-E2; n=173 DRSP-EE) | 4.1 (2.4) | 6.8 (22.3) |

Cycle 9 (n=356 NOMAC-E2; n=165 DRSP-EE) | 3.9 (2.2) | 6.9 (22.8) |

Cycle 10 (n=344 NOMAC-E2; n=162 DRSP-EE) | 4.2 (2.8) | 6.8 (23.0) |

Cycle 11 (n=300 NOMAC-E2; n=154 DRSP-EE) | 3.8 (1.9) | 6.8 (23.6) |

Cycle 12 (n=287 NOMAC-E2; n=142 DRSP-EE) | 3.8 (2.5) | 6.9 (24.6) |

Cycle 13 (n=196 NOMAC-E2; n=126 DRSP-EE) | 2.8 (2.3) | 4.3 (1.6) |

No statistical analysis provided for Average Number of Withdrawal Bleeding/Spotting Days

Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data |
---|

No text entered. |